{ "@context": "https://frontierpicks.com/schemas/dossier.v1.json", "ticker": "AGL", "name": "agilon health, inc.", "url": "https://frontierpicks.com/dossiers/AGL/", "json_url": "https://frontierpicks.com/dossiers/AGL.json", "status": "DORMANT", "current_conviction": "LOW", "graded_conviction": null, "archetype": { "code": "a4", "n": 4 }, "current_thesis": "agilon health’s re-rating depends on Q3 confirming margin repair after its September partnership expansion. Medical margin of at least $105 million with the annual outlook intact would validate the operating case; a weekly close below $80 would invalidate the market case.", "invalidation_trigger": "A weekly close below $80 ends the re-rating thesis; Q3 medical margin below the company’s $105 million guided floor or a reduction in the full-year $465 million medical-margin floor would also contradict the operating case.", "catalyst_date": null, "outcome": "OPEN", "outcome_date": null, "invalidation_fired": null, "themes": [ "managed-care-health-services" ], "tags": [], "sources": [], "notes": [ "Revenue is booked gross of medical costs; medical margin, not revenue, is the operative line for this model.", "Quarterly results carry prior-period risk-adjustment true-ups, so Q2's $197M medical margin is not a run-rate — the company guides Q3 to $105–$115M.", "ACO REACH's final performance year is 2026 under CMS model design, which changes the 2027 member base (about 112,000 REACH members at Q2 2026).", "No Q3 2026 earnings date had been announced as of 2026-09-06; the prior-year date-setting release came on 2025-10-06." ], "body_markdown": "## Current Thesis\n\nagilon health’s re-rating thesis depends on Q3 confirming margin repair: medical margin of at least $105 million with the annual outlook intact would support it, while a weekly close below $80 would break the market case. Those operating benchmarks come from the company’s 2026-08-05 guidance; $80 remains the research invalidation threshold published on 2026-09-06.\n\nThe refresh changes the earlier claim that no partnership development had followed earnings. On 2026-09-10, agilon announced that Family Practice Center would join a Senior Health Connect accountable care organization (ACO) participating in the Medicare Shared Savings Program (MSSP). The announcement identifies an expansion channel but supplies no incremental membership, revenue or earnings contribution. [Company announcement](https://www.agilonhealth.com/news/press-release/agilon-health-and-family-practice-center-expand-relationship-through-senior-health-connect-aco/)\n\nThe narrative is maturing — Bernstein’s 2026-09-15 upgrade extends recognition of the August margin recovery, but the 2026-09-18 reference close remains 31.3% below the market’s $129.84 trailing-year high. This is an inference from analyst recognition and price structure, not a measurement of investor flows. A recovery above that high accompanied by quantified expansion would contradict this lifecycle assessment. [Bernstein rating coverage](https://finance.yahoo.com/markets/stocks/articles/bernstein-upgrades-agilon-health-outperform-102925170.html)\n\n## Bull Case\n\n- **Margin repair has reported evidence.** The 2026-08-05 results reported Q2 medical margin of $197 million versus negative $53 million a year earlier. That establishes a quarterly improvement; persistence remains subject to the Q3 test. [Q2 results](https://investors.agilonhealth.com/news/news-details/2026/agilon-health-Reports-Second-Quarter-2026-Results/default.aspx)\n- **Expansion now has a named partner.** The 2026-09-10 Family Practice Center announcement provides concrete partnership evidence after the previous note. It does not quantify replacement economics for the existing ACO business. [Company announcement](https://www.agilonhealth.com/news/press-release/agilon-health-and-family-practice-center-expand-relationship-through-senior-health-connect-aco/)\n- **Analyst support broadened in September.** Bernstein upgraded agilon to Outperform from Market Perform on 2026-09-15 and raised its target to $125 from $86. These are Bernstein’s valuation judgments, not company guidance. [MT Newswires](https://finance.yahoo.com/markets/stocks/articles/bernstein-upgrades-agilon-health-outperform-102925170.html)\n\n## Bear Case\n\n- **Guidance already anticipates lower profitability.** On 2026-08-05, agilon guided Q3 medical margin to $105–$115 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) to negative $5 million through positive $5 million. The company does not project repetition of Q2’s margin. [Q2 results](https://investors.agilonhealth.com/news/news-details/2026/agilon-health-Reports-Second-Quarter-2026-Results/default.aspx)\n- **Membership recovery remains unquantified.** Q2 platform membership was 549,000, down about 10% year over year, according to the 2026-08-05 results. The 2026-09-10 expansion release supplies no incremental enrollment figure against that contraction. [Partnership disclosure](https://www.agilonhealth.com/news/press-release/agilon-health-and-family-practice-center-expand-relationship-through-senior-health-connect-aco/)\n- **Market confirmation remains absent.** The adjusted price series through 2026-09-18 records a three-month decline of 21.2%, despite the September upgrade. That observation does not establish whether the cause is operating skepticism, sector pressure or selling by a particular investor group.\n\n## Setup & Price Structure\n\nThe market’s 2026-09-18 adjusted daily close was $89.16. The 14-day relative strength index (RSI) was 42.6, while the trailing-year high was $129.84. These supplied measurements establish a depressed price relative to its high; they do not establish a completed base. No moving-average value or slope is available to substantiate a rising-average support claim.\n\nThe $80 threshold is retained as the published research boundary, not presented as newly verified chart support. Bernstein’s $125 target dated 2026-09-15 is an analyst valuation reference, not an observed breakout level.\n\nCrowding evidence is limited. The two Benzinga roundup headlines dated 2026-09-15 cover the same upgrade, so their clustering cannot establish independent participation. The latest supplied short-interest snapshot is dated 2026-08-31 and reports about 7.50% of float short, according to MarketBeat/Fintel screens; it does not establish positioning after the conferences. The sample is too small to support a retail-crowding claim. [Upgrade record](https://www.benzinga.com/quote/agl/price-targets)\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-30 — Q3 reporting period ends.** This is the accounting cutoff identified in the 2026-08-05 guidance, not a scheduled results announcement. The eventual report tests the medical-margin benchmark. [Company guidance](https://investors.agilonhealth.com/news/news-details/2026/agilon-health-Reports-Second-Quarter-2026-Results/default.aspx)\n\nFor 2026-09-20 through 2026-10-20, no confirmed company catalyst was identified on the reviewed events page. The announced conference dates of 2026-09-09, 2026-09-14 and 2026-09-16 have elapsed. No Q3 announcement date was verified, so the earlier estimated dates are not treated as scheduled events. [Events calendar](https://investors.agilonhealth.com/events-and-presentations/), [conference announcement](https://investors.agilonhealth.com/news/news-details/2026/agilon-health-to-Participate-in-Upcoming-Conferences-7c2d377f8/default.aspx)\n\n## What Would Change Our Mind\n\nFailure of the published market boundary would end the re-rating case: a weekly close below $80 is the observable price condition. Operating evidence would also contradict the thesis if Q3 medical margin falls below the company’s 2026-08-05 floor of $105 million, or management reduces the full-year medical-margin floor of $465 million.\n\nConversely, Q3 medical margin at or above $105 million with the $465–$505 million annual outlook maintained, before the price invalidation occurs, would satisfy the immediate operating case. Quantified membership and earnings contributions from the 2026-09-10 partnership would separately strengthen the expansion argument; the announcement alone cannot settle it.\n\n## Correlation Notes\n\nThis remains a single-name turnaround assessment. The 2026-08-05 margin recovery and the 2026-09-10 partnership announcement are company-specific evidence; the managed-care theme tag describes business exposure rather than measured co-movement. No matched peer-return series is available, so a sector-correlation claim is unsupported.", "first_seen": "2026-09-04", "last_analyzed": "2026-09-20T08:07:04+00:00", "last_synthesized": "2026-09-19", "last_update_source": "research_universe", "license": "Content © FrontierPicks. Cite the canonical URL." }